10-K: Humana Inc. Reports Full-Year 2024 Results, Navigates Medicare Advantage Challenges

Humana Inc.'s 2024 10-K filing reveals a year of growth in premiums and services revenue, offset by challenges in Medicare Advantage and strategic shifts in its commercial business.

Summary

• Humana Inc. reported its financial results for the year ended December 31, 2024.
• The company experienced growth in premiums and services revenue, driven by its Insurance and CenterWell segments.
• Net income attributable to Humana was $1.2 billion, or $9.98 per diluted common share, compared to $2.5 billion, or $20.00 per diluted common share, in the previous year.
• The company is exiting the Employer Group Commercial Medical Products business, anticipating finalization in the first half of 2025.
• Humana is facing challenges in its Medicare Advantage program, including a significant decline in Star Ratings for 2025.
• The company has filed a lawsuit challenging the 2025 Star Ratings and the CMS's RADV audit methodology.
• Humana is managing risks associated with government contracts, cybersecurity, and legal proceedings.
• The company is focused on its integrated care delivery model and the growth of its CenterWell businesses.
• Humana is committed to recruiting, developing, and retaining a diverse workforce.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's growth in some areas, challenges in Medicare Advantage and strategic shifts create uncertainty. The legal proceedings and regulatory risks add to the neutral outlook.

Positives

• Total premiums and services revenue increased by 10.7% to $117.76 billion in 2024.
• Individual Medicare Advantage membership reached 5,661,800, a 4.7% increase from the previous year.
• CenterWell segment services revenue increased by 14.2% to $3.465 billion.
• The company is committed to recruiting, developing, and retaining a diverse workforce.

Negatives

• Net income attributable to Humana decreased to $1.2 billion, or $9.98 per diluted common share, compared to $2.5 billion, or $20.00 per diluted common share, in the previous year.
• Approximately 25% of Humana's Medicare Advantage members are in plans rated 4-star or higher for 2025, a significant drop from 94% in 2024.
• The company is exiting the Employer Group Commercial Medical Products business, expecting to finalize the exit in the first half of 2025.

Risks

• The company faces risks related to government regulations, including changes to Medicare Advantage and Part D programs.
• Humana is involved in various legal actions and governmental investigations, which could result in substantial monetary damages or changes in business practices.
• The company is exposed to cybersecurity attacks and data breaches, which could disrupt operations and lead to financial losses.
• Humana's business is highly competitive, and the company faces pressure to contain premium prices.
• The company's future performance depends on its ability to effectively implement its operational and strategic initiatives.

Future Outlook

For the full year 2025, Humana anticipates a net membership decline in its individual Medicare Advantage offerings of approximately 550,000 members and net membership growth in its state-based contracts of approximately 175,000 to 250,000 members. The company anticipates net membership growth in its group Medicare Advantage offerings to be relatively flat and net membership growth in its Medicare stand-alone PDP offerings of approximately 200,000 members.

Industry Context

The health benefits industry is highly competitive, with competitors varying by local market and including other managed care companies, national insurance companies, and other HMOs and PPOs.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A thorough comparison would require detailed benchmarking data from competitors like UnitedHealth Group, CVS Health (Aetna), and Cigna, as well as industry-specific metrics from organizations like the National Committee for Quality Assurance (NCQA).
• Without specific data on key performance indicators (KPIs) such as medical loss ratio (MLR), administrative expense ratio, customer satisfaction scores, and Star Ratings compared to industry averages, a comprehensive assessment is not possible.

Management Changes

Legal Proceedings

• Humana is involved in a lawsuit against the United States Department of Health and Human Services regarding the RADV audit methodology.
• The company is also facing a putative stockholder class action and related derivative actions alleging false or misleading statements about its financial performance and Medicare Advantage business.
• Humana settled the claims in the qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc, and paid the United States $90 million.

Stakeholder Impact

• Shareholders may be affected by the company's financial performance and the outcome of legal proceedings.
• Employees may be impacted by workforce optimization initiatives and changes in compensation and benefits.
• Members may experience changes in benefits and access to care due to the company's strategic shifts and regulatory challenges.
• Providers may be affected by changes in reimbursement rates and contract terms.

Next Steps

• Humana will continue to execute its strategy, including opportunities created by the expansion of its Medicare programs, its strategy with respect to state-based contracts, the growth of its pharmacy, primary care, and home solutions businesses, and the successful implementation of its integrated care delivery model.
• The company will continue to defend against allegations in the In re Humana Inc. Securities Litigation and related stockholder derivative actions.
• Humana will continue to pursue its lawsuit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside.

Key Dates

Keywords

Humana, Medicare Advantage, CenterWell, Financial Results, Star Ratings, Risk Adjustment, Government Contracts, Healthcare, Insurance, Medicaid